Loading clinical trials...
Loading clinical trials...
A 16-week, Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel Group Study to Evaluate the Efficacy of Rivastigmine Patch (10 cm²) on Cognitive Deficits in Patients With Multiple Sclerosis, Followed by a 1-year Open-label Treatment Phase
Conditions
Interventions
Rivastigmine transdermal patch
Placebo
Locations
49
Germany
Novartis Investigative Site
Aachen, Germany
Novartis Investigative Site
Aalen, Germany
Novartis Investigative Site
Abensberg, Germany
Novartis Investigative Site
Achim, Germany
Novartis Investigative Site
Alzenau in Unterfranken, Germany
Novartis Investigative Site
Aschaffenburg, Germany
Start Date
April 1, 2009
Primary Completion Date
January 1, 2011
Completion Date
January 1, 2011
Last Updated
March 12, 2012
NCT07225504
NCT06276634
NCT07220668
NCT06154174
NCT06809192
NCT04123314
Lead Sponsor
Novartis Pharmaceuticals
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions